NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma

https://tandfonline.com/doi/full/10.1080/2162402X.2018.1561106
Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma
Tanner M. Johanns, Christopher A. Miller, Connor J. Liu, Richard J. Perrin, Diane Bender, Dale K. Kobayashi, show all
Article: e1561106 | Received 08 Oct 2018, Accepted 10 Dec 2018, Published online: 25 Jan 2019
Download citation https://doi.org/10.1080/2162402X.2018.1561106

Tanner M. Johanns, Christopher A. Miller, Connor J. Liu, Richard J. Perrin, Diane Bender, Dale K. Kobayashi, Jian L. Campian, Michael R. Chicoine, Ralph G. Dacey, Jiayi Huang, Edward F. Fritsch, William E. Gillanders, Maxim N. Artyomov, Elaine R. Mardis, Robert D. Schreiber & Gavin P. Dunn
Article: e1561106 | Received 08 Oct 2018, Accepted 10 Dec 2018, Published online: 25 Jan 2019
Download citation https://doi.org/10.1080/2162402X.2018.1561106

includes:

Here, we report a patient with glioblastoma (GBM) treated with a heterologous personalized vaccine, including an autologous tumor lysate-dendritic cell vaccine (DCVax) followed by a neoantigen-based synthetic long peptide vaccine (GBM.PVax). Analysis of post-treatment peripheral blood demonstrated detectable neoantigen-specific CD8+ and CD4+ T cell responses after peptide vaccination. Similar responses were observed in post-treatment tumor-infiltrating lymphocytes (TIL). Furthermore, genomic and transcriptomic characterization of the mutational landscape and tumor microenvironment pre- and post-treatment demonstrated tumor clonal evolution and evidence of potential immune evasion. Together, these results support the evaluation of immunogenomics-based vaccine strategies in glioblastoma and other tumors exhibiting moderate mutational loads.

and

Prior to surgery, the patient had consented to an autologous tumor lysate-dendritic cell vaccine study (DCVax-L) (NCT00045968) and an institutional personalized neoantigen-based peptide vaccine study (GBM.PVax) (NCT02510950). Therefore, following 6 weeks of standard adjuvant radiation therapy and concurrent temozolomide chemotherapy (CCRT), the patient received DCVax-L plus temozolomide during GBM.PVax preparation (Figure 1). DCVax-L was administered off-trial due to radiographic pseudoprogression noted following CCRT (data not shown). After cycle 4 of DCVax-L, GBM.PVax manufacturing was complete so DCVax-L was discontinued and GBM.PVax was initiated.

This article may prove to be an interesting read for some. (I wonder if Northwest Bio is aware of this case study?)